NASDAQ: PSTXPoseida Therapeutics Inc Stock
$2.07-0.09 (-4.17%)
Updated Apr 24, 2024
PSTX Price
$2.07
Fair Value Price
N/A
Market Cap
$199.73M
52 Week Low
$1.54
52 Week High
$4.27
P/E
-1.51x
P/B
1.93x
P/S
4.68x
PEG
N/A
Dividend Yield
N/A
Revenue
$64.70M
Earnings
-$123.43M
Gross Margin
100%
Operating Margin
-177.2%
Profit Margin
-190.8%
Debt to Equity
1.64
Operating Cash Flow
-$92M
Beta
1.41
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PSTX Overview
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PSTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PSTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PSTX is good value based on its book value relative to its share price (1.93x), compared to the US Biotechnology industry average (5.86x)
P/B vs Industry Valuation
PSTX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PSTX due diligence checks available for Premium users.
Be the first to know about important PSTX news, forecast changes, insider trades & much more!
PSTX News
Valuation
PSTX fair value
Fair Value of PSTX stock based on Discounted Cash Flow (DCF)
Price
$2.07
Fair Value
-$0.01
Undervalued by
28,915.43%
PSTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PSTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.51x
Industry
15.69x
Market
41.27x
PSTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.93x
Industry
5.86x
PSTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PSTX's financial health
Profit margin
Revenue
$25.0M
Net Income
-$25.3M
Profit Margin
-101.4%
PSTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PSTX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$273.9M
Liabilities
$170.2M
Debt to equity
1.64
PSTX's short-term assets ($226.48M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PSTX's short-term assets ($226.48M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PSTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PSTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$28.7M
Investing
$47.7M
Financing
$0.0
PSTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PSTX vs Biotech Stocks
Poseida Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.